(CercleFinance.com) – Bristol Myers Squibb announces that the European Commission has approved its Opdivo as monotherapy for the adjuvant treatment of adults and adolescents aged 12 and over with stage IIB or IIC melanoma who have undergone complete resection.
This approval in the European Union is based on results from the Phase III CheckMate -76K trial in patients with stage IIB or IIC melanoma, in which Opdivo reduced the risk of recurrence or death by 58 % compared to placebo.
‘Opdivo is now the only PD-1 inhibitor which, between two approvals, is indicated as an adjuvant treatment in resected melanomas of stages IIB, IIC, III, as well as stage IV’, highlights the pharmaceutical laboratory.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
